Limba
Romanian
Romanian
English|
JNJ-10198409, a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase)inhibitor with IC50 of 2 nM, is a dual-mechanism, antiangiogenic, and tumor cell antiproliferativeagent, has good activity against PDGFRβ kinase and PDGFRα kinasewith IC50 of 4.2 and 45 nM, respectively.
| Price | 1.768,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
JNJ-10198409, a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase)inhibitor with IC50 of 2 nM, is a dual-mechanism, antiangiogenic, and tumor cell antiproliferativeagent, has good activity against PDGFRβ kinase and PDGFRα kinasewith IC50 of 4.2 and 45 nM, respectively. |
